← back to search

Paul P. Tak

Stanford University · US
Area of research
Rheumatology · Radiology, Nuclear Medicine and Imaging
Research interest
Research interests include Rheumatoid Arthritis Research and Therapies, Systemic Lupus Erythematosus Research, Spondyloarthritis Studies and Treatments, and Monoclonal and Polyclonal Antibodies Research.
h-index
120
citations
61,714
works
624
NIH funding
primary concept
email

Recent publications

Association of response to TNF inhibitors in rheumatoid arthritis with quantitative trait loci for CD40 and CD39
Annals of the Rheumatic Diseases 2019cited by 40position: middledoi
Promotion of macrophage activation by Tie2 in the context of the inflamed synovia of rheumatoid arthritis and psoriatic arthritis patients
Lara D. Veeken 2019cited by 28position: middledoi
Adherence to Treat-to-target Management in Rheumatoid Arthritis and Associated Factors: Data from the International RA BIODAM Cohort
The Journal of Rheumatology 2019cited by 23position: middledoi
Effects of B-cell directed therapy on the preclinical stage of rheumatoid arthritis: the PRAIRI study
Annals of the Rheumatic Diseases 2018cited by 286position: lastdoi
Genome-wide association study of response to methotrexate in early rheumatoid arthritis patients
The Pharmacogenomics Journal 2018cited by 51position: middledoi
Synovial tissue research: a state-of-the-art review
Nature Reviews Rheumatology 2017cited by 256position: middledoi
Crowdsourced assessment of common genetic contribution to predicting anti-TNF treatment response in rheumatoid arthritis
Nature Communications 2016cited by 87position: middledoi
TYK2 Protein-Coding Variants Protect against Rheumatoid Arthritis and Autoimmunity, with No Evidence of Major Pleiotropic Effects on Non-Autoimmune Complex Traits
PLoS ONE 2015cited by 152position: middledoi
DNA Methylome Signature in Synoviocytes From Patients With Early Rheumatoid Arthritis Compared to Synoviocytes From Patients With Longstanding Rheumatoid Arthritis
Arthritis & Rheumatology 2015cited by 81position: middledoi
MOR103, a human monoclonal antibody to granulocyte–macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial
Annals of the Rheumatic Diseases 2014cited by 151position: middledoi
Integration of Sequence Data from a Consanguineous Family with Genetic Data from an Outbred Population Identifies PLB1 as a Candidate Rheumatoid Arthritis Risk Gene
PLoS ONE 2014cited by 149position: middledoi
Inhibition of osteoclastogenesis and inflammatory bone resorption by targeting BET proteins and epigenetic regulation
Nature Communications 2014cited by 141position: middledoi
A genome-wide association study of rheumatoid arthritis without antibodies against citrullinated peptides
Annals of the Rheumatic Diseases 2014cited by 77position: middledoi
Genetics of rheumatoid arthritis contributes to biology and drug discovery
Nature 2013cited by 2,460position: middledoi
Features of the Synovium of Individuals at Risk of Developing Rheumatoid Arthritis: Implications for Understanding Preclinical Rheumatoid Arthritis
Arthritis & Rheumatology 2013cited by 181position: lastdoi
Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up
Lara D. Veeken 2013cited by 129position: middledoi
The resolution of inflammation
Nature reviews. Immunology 2012cited by 556position: lastdoi
EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis
Annals of the Rheumatic Diseases 2012cited by 467position: lastdoi
The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project)
Annals of the Rheumatic Diseases 2012cited by 317position: middledoi
Genome-wide association analysis of anti-TNF drug response in patients with rheumatoid arthritis
Annals of the Rheumatic Diseases 2012cited by 100position: middledoi
Impact of intravenous abatacept on synovitis, osteitis and structural damage in patients with rheumatoid arthritis and an inadequate response to methotrexate: the ASSET randomised controlled trial
Annals of the Rheumatic Diseases 2012cited by 63position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

· 3 papers (2013–2018)Man Tang · Qinghai University2 papers (2018–2019)Lars Klareskog · Karolinska University Hospital2 papers (2012–2013) · 1 papers (2013–2013)Kyung-Hyun Park-Min · Hospital for Special Surgery1 papers (2014–2014) · 1 papers (2014–2014)Maria J. H. de Hair · University of Amsterdam1 papers (2013–2013)Manuela Le Bars · University of Colorado Denver1 papers (2012–2012) · 1 papers (2013–2013)Gerd‐Rüdiger Burmester · Humboldt-Universität zu Berlin1 papers (2012–2012)Robert Landewé · Reade1 papers (2013–2013)John W. Whitaker · Semtech (United States)1 papers (2015–2015)David M. Goldenberg · Stanford University1 papers (2013–2013) · 1 papers (2014–2014)Andrea Rubbert‐Roth · University of St.Gallen1 papers (2014–2014) · 1 papers (2014–2014) · 1 papers (2014–2014)Vibeke Strand · Stanford University1 papers (2013–2013)Frank Behrens · Goethe University Frankfurt1 papers (2014–2014)Kenneth Kalunian · University of California System1 papers (2013–2013)